{"id":1174,"date":"2026-09-23T08:39:00","date_gmt":"2026-09-23T12:39:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=1174"},"modified":"2026-09-19T16:43:21","modified_gmt":"2026-09-19T20:43:21","slug":"off-label-drug-sales-demand-looks-like-growth-until-it-doesnt","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/off-label-drug-sales-demand-looks-like-growth-until-it-doesnt\/","title":{"rendered":"Off-Label Drug Sales Demand Looks Like Growth. Until It Doesn’t."},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

In January 2026, Hims & Hers launched a compounded oral semaglutide pill priced at $49 for the first month. Nine days later, Novo Nordisk had filed a federal patent lawsuit, the Department of Health and Human Services had referred the company to the Department of Justice, and Hims & Hers stock had fallen more than 20% in a single session.[1][2]<\/sup> Eleven months earlier, a different regulatory event \u2014 the FDA’s February 21, 2025 determination that the semaglutide shortage was resolved \u2014 had already erased 26% of the company’s market value in one day and forced it to warn subscribers to find “alternative options” for their weight-loss prescriptions.[3][4]<\/sup><\/p>\n\n\n\n

Both events trace back to the same underlying mechanic: off-label and compounded demand for GLP-1 receptor agonists scaled fast because a legal shortage exemption made it possible, and it kept threatening to collapse every time the FDA closed that exemption. This is not a story unique to weight-loss drugs. The same four-stage pattern \u2014 access gap, gray-market scaling, regulatory reset, demand cliff \u2014 shows up in the testosterone “Low T” boom of the 2000s and 2010s, with a rise and fall large enough that researchers could measure it in tens of millions of insurance claims.[5]<\/sup><\/p>\n\n\n\n

This article reconstructs both timelines using FDA decision memoranda, SEC filings, and peer-reviewed prescribing data, and builds a general framework for recognizing when off-label demand is a durable growth signal versus a temporary artifact of supply, price, or regulatory ambiguity.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

Off-label and compounded demand tends to expand fastest under exactly the conditions regulators intend to be temporary: drug shortages, unclear enforcement priorities, or a price gap between an approved product and an unapproved substitute. When the FDA closes the shortage, clarifies enforcement, or a label change narrows the approved population, that demand does not gradually taper \u2014 it drops sharply, often within one or two fiscal quarters. Semaglutide compounding and testosterone’s “Low T” era both show 40%\u201360%-plus declines in the relevant demand measure within roughly three years of the triggering regulatory action.[5][6]<\/sup><\/p>\n\n\n\n

1. What “Off-Label” Actually Means \u2014 And What It Doesn’t<\/strong><\/h2>\n\n\n\n

Off-label prescribing is legal. Once the FDA approves a drug, physicians may prescribe it for any indication, dose, or patient population they judge appropriate, even outside the approved label.[7]<\/sup> What the FDA restricts is manufacturer promotion<\/em> of unapproved uses, and, separately, who is allowed to compound<\/em> a copy of an approved drug and under what conditions.<\/p>\n\n\n\n

Compounding operates under two statutory pathways: Section 503A, which covers state-licensed pharmacies and physicians compounding for individual patients, and Section 503B, which covers “outsourcing facilities” that can compound at scale without a patient-specific prescription.[8]<\/sup> Both pathways are subject to an “essentially a copy” restriction \u2014 compounders generally cannot make a product that is nearly identical to an already-approved drug. The exception: when that approved drug is officially listed on the FDA’s drug shortage list. Once a shortage is declared, the essentially-a-copy restriction lifts, and compounding pharmacies can legally produce drugs that would otherwise infringe on an approved product’s exclusivity.[9]<\/sup><\/p>\n\n\n\n

That single regulatory switch \u2014 shortage listed versus shortage resolved \u2014 is the hinge on which the entire GLP-1 compounding market turned.<\/p>\n\n\n\n

2. The Off-Label Demand Cycle: A Framework<\/strong><\/h2>\n\n\n\n

Reconstructing the semaglutide and testosterone timelines side by side surfaces a repeatable four-stage pattern. This is an original classification built from the two case studies below, not an established regulatory or industry taxonomy.<\/p>\n\n\n\n

Stage 1 \u2014 The Access Gap<\/strong><\/h3>\n\n\n\n

Demand for an approved drug outpaces supply (a manufacturing shortage) or outpaces willingness to pay (a coverage or price gap). Regulators tolerate a workaround \u2014 shortage-based compounding, permissive marketing, silence on enforcement \u2014 because blocking it would leave patients without treatment.<\/p>\n\n\n\n

Stage 2 \u2014 Gray-Market Scaling<\/strong><\/h3>\n\n\n\n

Commercial actors build businesses around the workaround. Because the workaround was designed for individual patient access, not industrial-scale substitution, the businesses that scale fastest are usually the ones stretching the exemption’s intended scope \u2014 mass-marketed “personalized” dosing, direct-to-consumer telehealth funnels, steep price undercutting of the branded product.<\/p>\n\n\n\n

Stage 3 \u2014 The Regulatory Reset<\/strong><\/h3>\n\n\n\n

The triggering condition resolves \u2014 supply catches up, a safety signal appears, a court rules, or an agency simply re-reads its own statute. The FDA (or a court) closes or narrows the exemption. This is rarely gradual: shortage resolutions, safety communications, and label changes are dated, published events, not slow drifts.<\/p>\n\n\n\n

Stage 4 \u2014 The Demand Cliff<\/strong><\/h3>\n\n\n\n

Volume built on the exemption does not have anywhere to go except back to the approved product, a competitor, or discontinuation. Because Stage 2 businesses were built on a price or access gap that has just been legally closed, the falloff shows up almost immediately in prescribing data, company revenue, and stock price \u2014 not over the multi-year horizon typical of ordinary demand cycles.<\/p>\n\n\n\n

3. Case Study One: The Semaglutide Compounding Boom<\/strong><\/h2>\n\n\n\n

Stage 1: The Shortage (2022\u20132024)<\/strong><\/h3>\n\n\n\n

The FDA added Novo Nordisk’s semaglutide injection products to its drug shortage list in stages, starting with Wegovy in March 2022 and Ozempic in August 2022, as demand for GLP-1 weight-loss treatment outpaced Novo Nordisk’s manufacturing capacity.[10]<\/sup> Eli Lilly’s competing tirzepatide (Mounjaro, Zepbound) was added to the shortage list on similar timing. Under the 503A\/503B shortage exemption, compounding pharmacies and outsourcing facilities became legally able to sell copies of both molecules.<\/p>\n\n\n\n

Stage 2: Gray-Market Scaling (2023\u20132024)<\/strong><\/h3>\n\n\n\n

Telehealth platforms built weight-loss businesses around compounded GLP-1 access. Hims & Hers, the largest publicly traded example, began selling compounded semaglutide injections in May 2024 and reported full-year 2024 revenue of $1.48 billion, up 69% from $872 million in 2023, with weight-loss offerings as the primary driver the company cited to investors.[11]<\/sup> Novo Nordisk publicly escalated legal pressure on compounders during this period, including a print campaign in The New York Times<\/em> and USA Today<\/em> warning patients to verify their semaglutide source.[1]<\/sup><\/p>\n\n\n\n

The scale of this parallel market is difficult to size precisely because compounded sales are not centrally reported, but Novo Nordisk’s own February 2026 court filing estimated that as many as 1.5 million Americans were using compounded GLP-1 drugs.[12]<\/sup> Separately, Novo Nordisk’s litigation testing claimed injectable compounded semaglutide samples contained impurities of up to 86%, and compounded oral versions up to 75% \u2014 an allegation from an interested litigant, not an FDA finding, and it should be read that way.[13]<\/sup><\/p>\n\n\n\n

Stage 3: The Regulatory Reset (October 2024\u2013May 2025)<\/strong><\/h3>\n\n\n\n

The reset happened in two steps, one molecule at a time:<\/p>\n\n\n\n

    \n
  • October 2, 2024:<\/strong> The FDA determined the tirzepatide injection shortage was resolved, after confirming with Eli Lilly that manufacturing capacity could meet national demand.[14]<\/sup><\/li>\n\n\n\n
  • February 21, 2025:<\/strong> The FDA determined the semaglutide injection shortage was resolved, based on a decision memorandum reviewing supply data submitted by Novo Nordisk.[15]<\/sup>[16]<\/sup><\/li>\n<\/ul>\n\n\n\n

    To limit disruption to patients already using compounded product, the FDA granted a wind-down period rather than immediate enforcement: 503A compounding pharmacies could continue compounding semaglutide “essentially a copy” products until April 22, 2025, and 503B outsourcing facilities until May 22, 2025.[17]<\/sup> Compounding trade groups sued to block the determination on both the tirzepatide and semaglutide rulings; the FDA reaffirmed its tirzepatide determination in a declaratory order on December 19, 2024, and litigation over the semaglutide determination was still active as of the deadlines.[18]<\/sup><\/p>\n\n\n\n

    Stage 4: The Demand Cliff (2025)<\/strong><\/h3>\n\n\n\n

    Hims & Hers shares fell approximately 26% on February 21, 2025, the day of the FDA’s semaglutide announcement.[3]<\/sup> The company’s own SEC filings are explicit about the mechanism: its Form 10-Q for the quarter ended June 30, 2025 states that shortage resolution “has constrained and is expected to continue to constrain” its ability to offer compounded semaglutide, and reports Wholesale Revenue of $8.0 million for the quarter, down 10% year-over-year.[19]<\/sup> On September 9, 2025, the FDA’s Center for Drug Evaluation and Research sent Hims & Hers (operating as Hers) a warning letter concluding its compounded semaglutide products were misbranded under sections 502(a) and 502(bb) of the Food, Drug, and Cosmetic Act.[20]<\/sup><\/p>\n\n\n\n

    4. The 2026 Relapse: A Second Demand Cliff<\/strong><\/h2>\n\n\n\n

    The pattern repeated within a year, compressed into days rather than months. On February 5, 2026, Hims & Hers launched a compounded oral semaglutide pill starting at $49 for the first month, undercutting Novo Nordisk’s newly launched, FDA-approved Wegovy pill, which Novo had priced around $149 for early users.[21]<\/sup> Novo Nordisk publicly called the product “illegal mass compounding” the same day.[21]<\/sup> On February 6, the FDA announced enforcement action against companies mass-marketing unapproved compounded GLP-1 products, and HHS General Counsel stated the department had referred Hims & Hers to the DOJ for potential FDCA violations.[21]<\/sup> Hims & Hers announced it would stop offering the product on February 7. Novo Nordisk filed its patent infringement suit \u2014 alleging willful infringement of U.S. Patent No. 8,129,343, which covers the semaglutide molecule \u2014 on February 9.[2][22]<\/sup><\/p>\n\n\n\n

    By the end of February 2026, Hims & Hers stock had fallen to a low of $13.74, a 78% decline from its 2025 peak near $70.[23]<\/sup> A subsequent proposed class action alleged that Hims & Hers’ compounded semaglutide, synthesized through a different chemical process than Novo’s biologically produced version, does not contain a genuinely equivalent active ingredient to Ozempic or Wegovy as advertised \u2014 a claim from plaintiffs’ counsel, not an adjudicated finding.[24]<\/sup><\/p>\n\n\n\n

    The compressed 2026 timeline \u2014 five days from product launch to DOJ referral, four more days to a federal lawsuit \u2014 illustrates how much faster Stage 3 resets can move once regulators and branded manufacturers have already built the enforcement playbook from the first cycle.<\/p>\n\n\n\n

    Date<\/th>Event<\/th>Stage<\/th>Source<\/th><\/tr>
    Mar\/Aug 2022<\/td>Wegovy, then Ozempic added to FDA drug shortage list<\/td>1 \u2014 Access gap opens<\/td>[10]<\/td><\/tr>
    May 2024<\/td>Hims & Hers begins selling compounded semaglutide injections<\/td>2 \u2014 Gray-market scaling<\/td>[21]<\/td><\/tr>
    Oct 2, 2024<\/td>FDA declares tirzepatide shortage resolved<\/td>3 \u2014 Reset (molecule 1)<\/td>[14]<\/td><\/tr>
    Feb 21, 2025<\/td>FDA declares semaglutide shortage resolved; stock falls ~26% same day<\/td>3\/4 \u2014 Reset and cliff<\/td>[3][15]<\/td><\/tr>
    Apr 22 \/ May 22, 2025<\/td>Compounding wind-down deadlines (503A \/ 503B)<\/td>3 \u2014 Reset enforced<\/td>[17]<\/td><\/tr>
    Sept 9, 2025<\/td>FDA warning letter to Hims & Hers (Hers) for misbranding<\/td>4 \u2014 Cliff, enforcement<\/td>[20]<\/td><\/tr>
    Feb 5, 2026<\/td>Hims & Hers launches $49 compounded oral pill<\/td>2 \u2014 Second scaling attempt<\/td>[21]<\/td><\/tr>
    Feb 6\u20139, 2026<\/td>FDA enforcement action, DOJ referral, Novo patent suit<\/td>3\/4 \u2014 Second reset and cliff<\/td>[21][2]<\/td><\/tr>
    Feb 27, 2026<\/td>Hims & Hers stock hits 78%-below-peak low of $13.74<\/td>4 \u2014 Cliff<\/td>[23]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    5. Case Study Two: The “Low T” Off-Label Boom<\/strong><\/h2>\n\n\n\n

    The same pattern is visible, and independently quantified in peer-reviewed literature, in testosterone prescribing over the previous decade \u2014 without a shortage or a compounding exemption involved at all, showing that the four-stage cycle is broader than GLP-1 supply dynamics.<\/p>\n\n\n\n

    Stage 1\u20132: Direct-to-Consumer “Low T” Marketing (2001\u20132013)<\/strong><\/h3>\n\n\n\n

    Testosterone use in the United States tripled between 2001 and 2011, driven substantially by prescribing to men without a clinically established cause of hypogonadism \u2014 effectively, off-label treatment of age-related testosterone decline, marketed to consumers as “Low T.”[25]<\/sup> An FDA analysis of national sales data found testosterone therapy use rose 65% from 2009 to 2013, with prescription volume climbing from 1.3 million in 2010 to 2.3 million by 2013; men aged 40\u201364 accounted for 70% of prescriptions and drove most of the increase.[26]<\/sup><\/p>\n\n\n\n

    Stage 3: The Regulatory Reset (2013\u20132015)<\/strong><\/h3>\n\n\n\n

    Two studies published in late 2013 and early 2014 \u2014 one in JAMA<\/em>, one in PLOS ONE<\/em> \u2014 reported associations between testosterone therapy and increased cardiovascular events.[27]<\/sup> The FDA issued a safety communication on January 31, 2014, followed by a public advisory committee meeting in September 2014, and a required label change in March 2015 that added a cardiovascular risk warning and restricted the approved population to men with hypogonadism from a defined medical cause \u2014 explicitly excluding age-related decline as an approved indication.[28][29]<\/sup><\/p>\n\n\n\n

    Stage 4: The Demand Cliff, Quantified (2013\u20132016)<\/strong><\/h3>\n\n\n\n

    A retrospective cohort study of nearly 10 million men over 30, using commercial claims data from 2002 through 2016, found testosterone prescribing fell 48% among established users and 62% among new users between 2013 and 2016.[6]<\/sup> The decline began before the label change itself: a 22% relative drop in new users followed the first cardiovascular study’s online publication in November 2013, with a further 50% relative decline over the following eight months as the second study and the FDA safety communication landed.[30]<\/sup> The reversal reached every age group and region, with the steepest relative decline \u2014 69% \u2014 among men 65 and older, the group most associated with age-related “Low T” marketing rather than classical hypogonadism.[30]<\/sup><\/p>\n\n\n\n

    \n

    Between 2013 and 2016, testosterone prescriptions fell 48% among established users and 62% among new users, following published cardiovascular-risk studies and an FDA safety communication \u2014 a decline researchers attribute directly to those regulatory and evidentiary events.[6]<\/sup><\/p>\n<\/blockquote>\n\n\n\n

    6. What the Two Cycles Have in Common<\/strong><\/h2>\n\n\n\n
    Dimension<\/th>Compounded Semaglutide<\/th>Testosterone (“Low T”)<\/th><\/tr>
    Mechanism enabling demand<\/td>Shortage-triggered 503A\/503B compounding exemption<\/td>Off-label prescribing for age-related decline, DTC marketing<\/td><\/tr>
    Peak-era growth signal<\/td>Hims & Hers revenue +69% in 2024[11]<\/sup><\/td>Prescriptions +65% 2009\u20132013[26]<\/sup><\/td><\/tr>
    Trigger for reset<\/td>FDA shortage-resolution determinations, 2024\u20132025<\/td>Cardiovascular studies + FDA safety communication, 2013\u20132014<\/td><\/tr>
    Formal reset mechanism<\/td>Loss of “essentially a copy” compounding exemption<\/td>Boxed warning + label restriction to defined hypogonadism<\/td><\/tr>
    Magnitude of decline<\/td>Wholesale revenue -10% YoY within one quarter of reset[19]<\/sup>; stock -78% peak-to-trough[23]<\/sup><\/td>-48% established users, -62% new users within 3 years[6]<\/sup><\/td><\/tr>
    Time from trigger to measurable decline<\/td>Same trading day (stock); one fiscal quarter (revenue)<\/td>Weeks (first relative drop in new users)[30]<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Both cycles share three structural features worth naming as findings in their own right:<\/p>\n\n\n\n

      \n
    1. The trigger is a dated, published regulatory or evidentiary event<\/strong> \u2014 a decision memorandum, a safety communication, a study publication \u2014 not a slow shift in prescriber sentiment. That is why the demand response is abrupt rather than gradual.<\/li>\n\n\n\n
    2. The steepest declines concentrate in new users, not existing ones.<\/strong> Established users often have inertia (an existing prescription, a treatment relationship); new-user volume is the more sensitive early indicator, and the one commercial and medical-affairs teams should watch first.<\/li>\n\n\n\n
    3. The commercial actors most exposed are the ones that scaled fastest during Stage 2<\/strong> \u2014 direct-to-consumer platforms and compounders in the GLP-1 case, high-volume “Low T” clinics in the testosterone case \u2014 because their entire growth thesis depended on the exemption or ambiguity persisting.<\/li>\n<\/ol>\n\n\n\n

      7. Why Off-Label Growth Is Structurally Unstable<\/strong><\/h2>\n\n\n\n

      The common failure mode is treating an exemption-driven demand curve as if it were a normal adoption curve. A normal adoption curve for an approved, on-label therapy responds to clinical evidence, competition, and pricing \u2014 all of which move gradually. An off-label or compounding-driven curve responds to a legal switch that a single federal agency can flip on a single published date. Growth built on the switch inherits the switch’s binary nature: durable until the day the exemption is confirmed closed, then abruptly not durable at all.<\/p>\n\n\n\n

      This has a direct forecasting implication for anyone modeling revenue, market share, or prescribing trends off a period when off-label or compounded volume is material: the compounded or off-label share of the base should be modeled separately from the on-label branded base, with an explicit assumption about when the exemption or ambiguity resolves \u2014 not blended into a single growth rate.<\/p>\n\n\n\n

      8. What This Means for Commercial and Brand Teams<\/strong><\/h2>\n\n\n\n

      Total prescription volume that includes a compounded or off-label component overstates the durable size of the branded market. The semaglutide case shows this concretely: Eli Lilly’s Mounjaro drove meaningful off-label weight-loss use before Zepbound’s 2023 approval, and once Zepbound launched with its own indication, some of that off-label demand simply relabeled itself as on-label demand for a different SKU rather than representing genuinely new patients.[31]<\/sup> Brand teams building market-size forecasts should separate the compounded\/off-label pool from the branded pool and track the regulatory calendar \u2014 shortage-list status, pending litigation deadlines \u2014 as a forecasting input, not an afterthought.<\/p>\n\n\n\n

      9. What This Means for Medical Affairs and Pharmacovigilance<\/strong><\/h2>\n\n\n\n

      Compounded products fall outside the FDA’s approval process for safety and efficacy, meaning adverse events associated with them may not route through the same reporting channels as events tied to an approved NDC.[8]<\/sup> Novo Nordisk’s litigation-stage impurity claims against compounded semaglutide \u2014 while an interested party’s allegation rather than an FDA finding \u2014 illustrate the category of signal Medical Affairs and PV teams should be positioned to evaluate independently: formulation variability, inactive-ingredient differences (such as benzyl alcohol, raised in the Hims & Hers class action), and dosing variability across compounding sources.[13][24]<\/sup><\/p>\n\n\n\n

      10. What This Means for Regulatory Affairs and Legal<\/strong><\/h2>\n\n\n\n

      The compounding exemption’s legal architecture is being tested in real time. Compounding trade associations have sued the FDA over both the tirzepatide and semaglutide shortage-resolution determinations, arguing the agency’s process was arbitrary; Novo Nordisk has separately pursued a patent-infringement theory against a compounder rather than relying solely on FDA enforcement.[18][22]<\/sup> Regulatory and legal teams tracking analogous exemptions elsewhere in a portfolio should treat both enforcement and<\/em> litigation outcomes as relevant precedent, since branded manufacturers in this cycle used both channels simultaneously rather than waiting on the FDA alone.<\/p>\n\n\n\n

      11. Where AI Drug Information Fits Into the Off-Label Picture<\/strong><\/h2>\n\n\n\n

      What the Evidence Shows About AI and Drug Information Accuracy<\/strong><\/h3>\n\n\n\n

      Off-label demand cycles create exactly the kind of ambiguous, fast-moving information environment where AI-generated drug answers are most likely to lag the current regulatory state. A 2025 cross-sectional study in BMJ Quality & Safety<\/em> tested an AI-powered chatbot integrated into a search engine against 500 patient questions about the 50 most-prescribed U.S. outpatient drugs, evaluating answers against drugs.com reference data and, for a flagged subset, against expert clinical judgment.[32]<\/sup> Chatbot statements did not match reference data in 126 of 484 evaluable answers (26%).[33]<\/sup> Of a subset of 20 answers flagged for low accuracy or completeness, medication-safety experts rated 66% as potentially harmful, including 22% rated capable of causing severe harm or death if a patient acted on the advice.[32]<\/sup><\/p>\n\n\n\n

      That study did not test off-label-specific queries, and its findings should not be generalized beyond the chatbot and question set it used. But the underlying risk it documents \u2014 a model blending regulated label content with forum discussion, pre-print literature, and outdated pages without flagging the difference \u2014 is structurally the same risk that applies to a compounded-drug or off-label question, where the “correct” answer can depend on a shortage-list status or an enforcement-discretion deadline that changes on a specific date.<\/p>\n\n\n\n

      How AI Monitoring Fits This Problem<\/strong><\/h3>\n\n\n\n

      This is the specific gap that AI-monitoring tools such as DrugChatter are built to track: comparing what large language models say about a drug’s approved indications, dosing, and safety information against the current prescribing information, and flagging where the two diverge.[34]<\/sup> For a molecule like semaglutide, where the compounding-legal status changed twice in eighteen months, that kind of ongoing comparison is a narrower and more tractable problem than general AI accuracy \u2014 the underlying facts to check against (shortage-list status, current label, active enforcement letters) are discrete and dated. This article does not include original DrugChatter testing data on off-label semaglutide queries specifically; the BMJ Quality & Safety findings above are the only AI-accuracy data cited here, and they come from an independent, peer-reviewed source rather than DrugChatter’s own monitoring.<\/p>\n\n\n\n

      Key Takeaways<\/strong><\/h2>\n\n\n\n
        \n
      • The FDA determined the tirzepatide shortage resolved on October 2, 2024, and the semaglutide shortage resolved on February 21, 2025, ending the compounding exemption that had enabled a parallel, unapproved GLP-1 market.[14][15]<\/sup><\/li>\n\n\n\n
      • Hims & Hers stock fell approximately 26% on the day of the semaglutide shortage-resolution announcement and had fallen 78% from its 2025 peak by February 27, 2026, following a second FDA enforcement action and a Novo Nordisk patent lawsuit.[3][23]<\/sup><\/li>\n\n\n\n
      • Novo Nordisk’s own 2026 court filing estimated 1.5 million Americans were using compounded GLP-1 drugs, illustrating the scale of off-label volume the 2025 and 2026 resets were built to unwind.[12]<\/sup><\/li>\n\n\n\n
      • A closely analogous cycle occurred with testosterone: prescriptions rose 65% from 2009 to 2013 on largely off-label, age-related use, then fell 48%\u201362% within three years of a 2014 FDA safety communication and 2015 label change.[6][26]<\/sup><\/li>\n\n\n\n
      • In both cases, the demand collapse followed a single dated regulatory or evidentiary event, not a gradual shift \u2014 the diagnostic signal to watch is new-user volume, which moves first and fastest.[30]<\/sup><\/li>\n\n\n\n
      • Independent, peer-reviewed testing has found AI chatbot drug answers can diverge meaningfully from reference sources, with a subset rated capable of causing severe patient harm \u2014 a risk that compounds in exactly the fast-changing, off-label-adjacent information environments these cycles create.[32]<\/sup><\/li>\n<\/ul>\n\n\n\n

        FAQ<\/strong><\/h2>\n\n\n\n

        Is it legal for a doctor to prescribe a drug off-label?<\/strong>
        Yes. Once the FDA approves a drug, physicians may legally prescribe it for any use they judge clinically appropriate. What is restricted is manufacturer promotion of unapproved uses, not physician prescribing itself.[7]<\/sup><\/p>\n\n\n\n

        Why was compounded semaglutide ever legal?<\/strong>
        Because Wegovy and Ozempic were on the FDA’s official drug shortage list from 2022 until February 2025, compounding pharmacies and outsourcing facilities were exempt from the usual restriction on copying an approved drug’s active ingredient.[9][10]<\/sup><\/p>\n\n\n\n

        When exactly did the FDA end the semaglutide shortage?<\/strong>
        February 21, 2025, based on a decision memorandum reviewing supply data from Novo Nordisk. The FDA allowed compounding pharmacies (503A) to continue until April 22, 2025, and outsourcing facilities (503B) until May 22, 2025, to limit disruption to existing patients.[15][17]<\/sup><\/p>\n\n\n\n

        Did compounded GLP-1 sales actually stop after the deadlines?<\/strong>
        Not entirely. Hims & Hers stated in its own SEC filings that it continued offering certain compounded GLP-1 products under separate statutory exemptions from new-drug approval requirements, and it launched a new compounded oral pill in February 2026 \u2014 which the FDA and Novo Nordisk moved against within days.[19][21]<\/sup><\/p>\n\n\n\n

        What did the FDA’s warning letter to Hims & Hers say?<\/strong>
        The FDA’s September 9, 2025 letter, signed by the director of the Center for Drug Evaluation and Research, concluded that the company’s compounded semaglutide products were misbranded under sections 502(a) and 502(bb) of the Food, Drug, and Cosmetic Act.[20]<\/sup><\/p>\n\n\n\n

        Is compounded semaglutide chemically identical to Ozempic or Wegovy?<\/strong>
        This is disputed in active litigation. Novo Nordisk has argued compounded and branded versions are “meaningfully different” due to different manufacturing processes, and a proposed class action makes a similar claim; these are allegations from parties with a financial or legal interest in the outcome, not settled FDA findings.[13][24]<\/sup><\/p>\n\n\n\n

        How big was the “Low T” testosterone boom, in numbers?<\/strong>
        FDA analysis of national sales data found testosterone prescriptions rose from 1.3 million in 2010 to 2.3 million in 2013, a 65% increase, concentrated in men aged 40\u201364.[26]<\/sup><\/p>\n\n\n\n

        What made testosterone prescribing fall so fast after 2013?<\/strong>
        Two cardiovascular-risk studies published in late 2013 and early 2014, followed by an FDA safety communication and a 2015 label change restricting the approved population, drove a 48% decline in established users and a 62% decline in new users by 2016.[6][27]<\/sup><\/p>\n\n\n\n

        Can AI chatbots be trusted to give accurate off-label or compounding-status information?<\/strong>
        Independent testing published in BMJ Quality & Safety<\/em> found that a widely used AI chatbot’s drug answers diverged from reference sources in 26% of evaluable cases, with a flagged subset rated by clinical experts as capable of causing moderate to severe harm. The study did not test off-label or compounding questions specifically, but its core finding \u2014 that chatbot answers blend regulated and unregulated sources without signaling which is which \u2014 applies directly to fast-changing shortage and enforcement-status questions.[32]<\/sup><\/p>\n\n\n\n

        What should commercial teams do differently when forecasting a market with meaningful off-label or compounded volume?<\/strong>
        Model the compounded\/off-label share separately from the on-label branded base, treat FDA shortage-list status and active litigation deadlines as forecasting inputs, and watch new-user or new-prescription volume as the earliest indicator of a demand reset \u2014 it moves before total volume or revenue does.[19][30]<\/sup><\/p>\n\n\n\n

        References<\/h2>\n\n\n\n
          \n
        1. Drug Discovery Trends. (2026, February 13). Novo Nordisk sues Hims for GLP-1 patent infringement<\/em>. https:\/\/www.drugdiscoverytrends.com\/novo-nordisk-sues-hims-for-glp-1-patent-infringement\/<\/li>\n\n\n\n
        2. CNBC. (2026, February 9). Novo Nordisk sues Hims & Hers over compounded obesity drugs<\/em>. https:\/\/www.cnbc.com\/2026\/02\/09\/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html<\/li>\n\n\n\n
        3. CNBC. (2025, February 21). Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage<\/em>. https:\/\/www.cnbc.com\/2025\/02\/21\/hims-hers-shares-fall-after-fda-says-semaglutide-no-longer-in-shortage.html<\/li>\n\n\n\n
        4. BioPharma Dive. (2025, February 25). Drug compounders sue FDA over declaration ending Wegovy shortage<\/em>. https:\/\/www.biopharmadive.com\/news\/drug-compounders-sue-fda-wegovy-shortage-hims-zepbound-price-cut\/740869\/<\/li>\n\n\n\n
        5. Baillargeon, J., et al. (2018). Testosterone prescribing in the United States, 2002-2016. JAMA, 320<\/em>(2), 200\u2013202.<\/li>\n\n\n\n
        6. ecancer. (n.d.). Testosterone prescriptions have sharply dropped in the past few years<\/em>. https:\/\/elsa.ecancer.org\/en\/news\/14374-testosterone-prescriptions-have-sharply-dropped-in-the-past-few-years<\/li>\n\n\n\n
        7. U.S. Food and Drug Administration. (2018). Understanding Unapproved Use of Approved Drugs “Off Label.”<\/em> https:\/\/www.fda.gov\/patients\/learn-about-expanded-access-and-other-treatment-options\/understanding-unapproved-use-approved-drugs-label<\/li>\n\n\n\n
        8. Alston & Bird. (2025, March). FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers<\/em>. https:\/\/www.alston.com\/en\/insights\/publications\/2025\/03\/fda-resolves-semaglutide-shortage<\/li>\n\n\n\n
        9. National Community Pharmacists Association. (2025, February 25). Semaglutide shortage is over, FDA says; grants discretion for compounding pharmacies<\/em>. https:\/\/ncpa.org\/newsroom\/qam\/2025\/02\/25\/semaglutide-shortage-over-fda-says-grants-discretion-compounding-pharmacies<\/li>\n\n\n\n
        10. Burr & Forman LLP. (n.d.). The FDA Removes Semaglutide from the Drug Shortage List<\/em>. https:\/\/www.burr.com\/newsroom\/articles\/the-fda-removes-semaglutide-from-the-drug-shortage-list<\/li>\n\n\n\n
        11. FierceHealthcare. (2025, February 25). Hims & Hers projects $2.3B in 2025 revenue despite uncertainty<\/em>. https:\/\/www.fiercehealthcare.com\/health-tech\/hims-hers-bullish-weight-loss-business-despite-glp-1-market-shift<\/li>\n\n\n\n
        12. CNBC. (2026, February 9). Novo Nordisk sues Hims & Hers over compounded obesity drugs<\/em>. https:\/\/www.cnbc.com\/2026\/02\/09\/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html<\/li>\n\n\n\n
        13. Novo Nordisk. (2026, February 9). Company statement<\/em>. https:\/\/www.novomedlink.com\/content\/dam\/novomedlink\/semaglutide\/02-09-2026-company-statement.pdf<\/li>\n\n\n\n
        14. U.S. Food and Drug Administration. (2024, October 2). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize<\/em>. https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize<\/li>\n\n\n\n
        15. U.S. Food and Drug Administration. (2025, February 21). Resolution of Semaglutide Injection Product Shortage and Supply Status<\/em> [Decision memorandum]. https:\/\/www.fda.gov\/media\/185526\/download<\/li>\n\n\n\n
        16. American Med Spa Association. (2025). FDA Announces Semaglutide Shortage Resolved<\/em>. https:\/\/www.americanmedspa.org\/news\/fda-announces-semaglutide-shortage-resolved\/<\/li>\n\n\n\n
        17. McDermott Will & Emery. (n.d.). Semaglutide Shortage Resolved<\/em>. https:\/\/www.mcdermottlaw.com\/insights\/semaglutide-shortage-resolved\/<\/li>\n\n\n\n
        18. Sheppard, Mullin, Richter & Hampton LLP. (2025, March 21). FDA’s Semaglutide Shortage Resolution: Legal Implications and Risks for Compounding Pharmacies<\/em>. https:\/\/www.sheppardhealthlaw.com\/2025\/03\/articles\/fda\/fdas-semaglutide-shortage-resolution-legal-implications-and-risks-for-compounding-pharmacies\/<\/li>\n\n\n\n
        19. Hims & Hers Health, Inc. (2025). Form 10-Q, quarter ended June 30, 2025<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1773751\/000177375125000250\/hims-20250630.htm<\/li>\n\n\n\n
        20. U.S. Food and Drug Administration. (2025, September 9). Warning Letter: Hims & Hers Health, Inc. dba Hers<\/em>. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/hims-hers-health-inc-dba-hers-716825-09092025<\/li>\n\n\n\n
        21. &AI Insights. (2026, February 18). Novo Nordisk Targets Hims & Hers’ Compounded Semaglutide Offerings in Patent Lawsuit<\/em>. https:\/\/www.tryandai.com\/blog\/novo-nordisk-sues-hims-for-patent-infringement-over-compounded-semaglutide<\/li>\n\n\n\n
        22. HMP Global Learning Network. (2026, February 10). Novo Nordisk Sues Hims & Hers as FDA Moves to Restrict Compounded GLP-1 Drugs<\/em>. https:\/\/www.hmpgloballearningnetwork.com\/site\/pln\/news\/novo-nordisk-sues-hims-hers-fda-moves-restrict-compounded-glp-1-drugs<\/li>\n\n\n\n
        23. TIKR. (2026, June 20). Hims & Hers Stock Fell 78% From Its Peak: What Comes After the GLP-1 Unwind<\/em>. https:\/\/www.tikr.com\/blog\/hims-hers-stock-fell-78-from-its-peak-what-comes-after-the-glp-1-unwind<\/li>\n\n\n\n
        24. ClassAction.org. (2026, February 27). Hims & Hers Lawsuit Says Compounded Semaglutide Does Not Have Same Active Ingredient as Ozempic, Wegovy as Advertised<\/em>. https:\/\/www.classaction.org\/news\/hims-and-hers-lawsuit-says-compounded-semaglutide-does-not-have-same-active-ingredient-as-ozempic-wegovy-as-advertised<\/li>\n\n\n\n
        25. Springer\/Nature Reviews Urology. (2018). Commentary on testosterone prescribing trends<\/em>. https:\/\/link.springer.com\/article\/10.1038\/s41585-018-0081-2<\/li>\n\n\n\n
        26. Indian Health Service National Pharmacy and Therapeutics Committee. (2015). Formulary Brief: Testosterone Replacement<\/em>. https:\/\/www.ihs.gov\/sites\/nptc\/themes\/responsive2017\/display_objects\/documents\/guidance\/NPTC-Formulary-Brief-Testosterone.pdf<\/li>\n\n\n\n
        27. Vigen, R., et al. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310<\/em>(17), 1829\u20131836.<\/li>\n\n\n\n
        28. U.S. Food and Drug Administration. (2015, March 3). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging<\/em>.<\/li>\n\n\n\n
        29. Wiley\/Clinical Endocrinology. (2018). The state of testosterone therapy since the FDA’s 2015 labelling changes: Indications and cardiovascular risk<\/em>. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.13589<\/li>\n\n\n\n
        30. Baillargeon, J., et al. (2018, Figure 1 & 2). Testosterone prescribing in the United States, 2002-2016. JAMA, 320<\/em>(2), 200\u2013202. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6396809<\/li>\n\n\n\n
        31. The Motley Fool. (2024, August 18). Forget Mounjaro: Eli Lilly’s Next Big Blockbuster<\/em>. https:\/\/www.fool.com\/investing\/2024\/08\/18\/forget-mounjaro-eli-lillys-next-big-blockbuster-ha<\/li>\n\n\n\n
        32. Andrikyan, W., Sametinger, S. M., Kosfeld, F., Jung-Poppe, L., Fromm, M. F., Maas, R., & Nicolaus, H. F. (2025). Artificial intelligence-powered chatbots in search engines: a cross-sectional study on the quality and risks of drug information for patients. BMJ Quality & Safety, 34<\/em>(2), 100. https:\/\/doi.org\/10.1136\/bmjqs-2024-017476<\/li>\n\n\n\n
        33. BMJ Group. (2024, October 15). Don’t rely on AI chatbots for accurate, safe drug information, patients warned<\/em> [Press release]. https:\/\/bmjgroup.com\/?p=8822<\/li>\n\n\n\n
        34. DrugChatter. (n.d.). AI Monitoring \u2014 DrugChatter<\/em>. https:\/\/www.drugchatter.com<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

          In January 2026, Hims & Hers launched a compounded oral semaglutide pill priced at $49 for the first month. Nine […]<\/p>\n","protected":false},"author":1,"featured_media":1182,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"modified_by":"DrugChatter","_links":{"self":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/comments?post=1174"}],"version-history":[{"count":1,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1174\/revisions"}],"predecessor-version":[{"id":1185,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1174\/revisions\/1185"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media\/1182"}],"wp:attachment":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media?parent=1174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/categories?post=1174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/tags?post=1174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}